Inclusion Criteria:

1. Any patient with a hematologic or oncologic diagnosis in which allogeneic HSCT is
thought to be beneficial, and in whom front-line therapy has already been applied.

2. Patients must have a related donor who is either a one, two or three out of six
antigen mismatch at the HLA-A;B;DR loci.

3. Patients without a well-matched unrelated donor or those who have a disease status
that precludes a wait for an identified unrelated donor.

4. Patients must adequate organ function:

- LVEF of >45%

- FVC or FEV1 >45% of predicted

- Adequate liver function as defined by a serum bilirubin <1.8, AST or ALT < 2.5X
upper limit of normal

- Serum creatinine < 2.0 mg/dl or creatinine clearance of > 40 ml/min

5. Performance status > 60% (Karnofsky)

6. Patients must be willing to use contraception if they have childbearing potential

7. Able to give informed consent

Exclusion Criteria:

1. An eligible HLA-identical sibling donor.

2. Performance status < 60% (Karnosfsky)

3. HIV positive

4. Active involvement of the central nervous system with malignancy

5. Psychiatric disorder that would preclude patients from signing an informed consent

6. Pregnancy

7. Patients with life expectancy of < 6 months for reasons other than their underlying
hematologic/oncologic disorder.